D and the Public Good

Ned Shaw Columnist George Will has observed that when the Titanic steamed into that iceberg, the disaster was not democratic: 56% of women sailing in third class died, while only four of 143 women in first class perished. You don't need to ask which class was traveling near or below the waterline. When it comes to healthcare research, development and delivery--or, to be more precise, the lack thereof--those closest to the "waterline" are less-developed countries. Health-related R&D has b

Written byHenry Miller
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Columnist George Will has observed that when the Titanic steamed into that iceberg, the disaster was not democratic: 56% of women sailing in third class died, while only four of 143 women in first class perished. You don't need to ask which class was traveling near or below the waterline.

When it comes to healthcare research, development and delivery--or, to be more precise, the lack thereof--those closest to the "waterline" are less-developed countries.

Health-related R&D has been designated officially as a "global public good" by the World Health Organization's (WHO) Commission on Macroeconomics and Health, reflecting the need for more and better medical research in less-developed countries. Unfortunately, such actions are largely symbolic; the real question is how do we translate lofty goals into real-world benefits. One model for the pursuit of projects particularly relevant to less-developed countries is a new global institute along the lines of "big science" undertakings ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies